Drug Trial Radar · NCT03226522
Addressing Dementia Via Agitation-Centered Evaluation
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Jul 13, 2017
Primary completion
Apr 17, 2020
Study completion Apr 17, 2020
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Alzheimer Disease
- Agitation,Psychomotor
Interventions
AXS-05Drug
AXS-05
BupropionDrug
Bupropion
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in CMAI Total ScoreTime frame: 5 weeks
Locations
78 sites in 2 countries. Site status is shown where the registry gives one.
Axsome Study Site
Gilbert, Arizona
Axsome Study Site
Phoenix, Arizona
Axsome study site
Scottsdale, Arizona
Axsome study site
Scottsdale, Arizona
Axsome Study Site
Tucson, Arizona
Axsome Study Site
Little Rock, Arkansas
Axsome study site
Canoga Park, California
Axsome study site
Costa Mesa, California
Axsome study site
Fresno, California
Axsome study site
Long Beach, California
Axsome study site
Long Beach, California
Axsome Study Site
Los Alamitos, California
Axsome study site
Riverside, California
Axsome study site
Sacramento, California
Axsome study site
Santa Ana, California
Axsome Study Site
Santa Clarita, California
Axsome study site
Sherman Oaks, California
Axsome study site
Simi Valley, California
Axsome study site
Temecula, California
Axsome study site
Ventura, California
Axsome Study Site
Colorado Springs, Colorado
Axsome study site
Cromwell, Connecticut
Axsome study site
New London, Connecticut
Axsome Study Site
Apopka, Florida
Axsome study site
Boca Raton, Florida
Axsome study site
Boynton Beach, Florida
Axsome Study Site
Coconut Creek, Florida
Axsome Study Site
Greenacres City, Florida
Axsome study site
Hallandale, Florida
Axsome study site
Hialeah, Florida
Axsome Study Site
Lake City, Florida
Axsome study site
Miami, Florida
Axsome study site
Miami, Florida
Axsome Study Site
Orlando, Florida
Axsome study site
Pensacola, Florida
Axsome Study Site
Port Orange, Florida
Axsome study site
Spring Hill, Florida
Axsome study site
Tampa, Florida
Axsome study site
Tampa, Florida
Axsome study site
Atlanta, Georgia
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.